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experiments blind and generally using 
poor experimental design were all 
fl aws in ethological work of that early 
period.
How did you become interested in 
animal welfare? An animal in pain 
or distress is not a suitable subject 
for the study of normal behaviour. 
The animal’s welfare and state of 
well-being were, therefore, important 
to ethologists and the undoubted 
ethical considerations added another 
dimension. I was tempted by a request 
from the National Trust to examine the 
welfare of deer hunted with hounds 
in the West of England. Though I had 
done nothing like this before — indeed 
nobody had — I thought it would be 
an interesting challenge. I had an able 
research associate in Liz Bradshaw 
and after a year and a half we reported 
to the Council of the National Trust, 
concluding that the level of total 
suffering of red deer would be markedly 
reduced if hunting with hounds were 
ended. Hunting red deer with hounds 
could no longer be justifi ed on welfare 
grounds, given the standards applied 
in other fi elds such as the transit and 
slaughter of farm animals and the use 
of animals in research. 
On the strength of our report, the 
National Trust immediately banned 
hunting of red deer with hounds on its 
land. Our study was the fi rst of its kind 
and was understandably controversial 
because it challenged the way of life of 
people living in stag-hunting country. 
They were determined to show that 
we were wrong and commissioned a 
new study; however, the new group 
obtained gratifyingly similar results 
to those obtained in our work, even 
though they had no interest in its 
welfare implications. 
In another foray into animal welfare, 
I conducted a survey of the breeding 
of pedigree dogs. Breeding for 
exaggerated characteristics like a 
fl attened face or sloping back clearly 
had welfare implications. So did close 
inbreeding conducted in the interests 
of retaining desired characteristics. 
My report was critical of what some 
breeders were doing, but this time 
it was like pushing on an open door 
and I received none of the odium that 
accompanied my report on stag-
hunting.
Has any theme run through your 
academic work? I have often 
attacked the distinction that is 
drawn in describing behavour as 
being either innate or acquired. The 
study of imprinting which occupied 
much of my research life provides 
an important insight into the 
development of behaviour. The bird 
has strong predispositions to respond 
socially to particular things and its 
capacity to develop preferences 
generates a robust outcome. 
Therefore, opposing robustness 
and the consequences of plasticity 
provides a misleading picture of 
what happens in development. For 
that reason I have advocated that 
processes of development should 
be the object of study. This is now 
part of the broader study of the 
fi eld known as epigenetics. In an 
attempt to understand the process, 
I was involved for many years in 
collaboration with neurobiologists, 
particularly Gabriel Horn. This work 
was crowned with identifying a crucial 
structure in the brain which is closely 
involved in imprinting. Epigenetics 
involves the active involvement of the 
individual in its own development. 
Shortly after hatching birds such as 
ducklings work to present themselves 
with an object with which they can be 
imprinted. The behaviour that leads 
a bird to an imprinting stimulus is 
reinforced, but the learning process is 
different from imprinting. 
 I retained an interest in the whole 
animal and the active role of its 
behaviour in development. Much of the 
work with my students and associates 
was on play in mammals. In writing 
about this in a recent book with one 
of my former students, Paul Martin, 
we concluded that play enables an 
individual to cope creatively with 
novel challenges later in its life. An 
individual’s activities not only affect its 
own development, they also impinge 
on the environment of its descendants. 
This provides one of the links between 
epigenetics and evolution. Bridging 
the gap between seemingly different 
questions that may be asked about 
behaviour is a trend that would have 
excited Niko Tinbergen. He was clear 
about the difference between the 
questions but also saw the value of 
bringing them together. That synthesis 
remains as important a contribution 
of ethology as it did in his day and 
has run as a theme throughout my 
academic life. 
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What are spliceosomes? 
Spliceosomes are huge, 
multimegadalton ribonucleoprotein 
(RNP) complexes found in eukaryotic 
nuclei. They assemble on RNA 
polymerase II transcripts from which 
they excise RNA sequences called 
introns and splice together the 
fl anking sequences called exons. 
This so-called pre-messenger RNA 
(pre-mRNA) splicing is an essential 
step in eukaryotic mRNA synthesis. 
Every human cell contains ~100,000 
spliceosomes, which are responsible 
for removing over 200,000 different 
intron sequences. Human cells 
contain two types of spliceosome: 
the major spliceosome responsible 
for removing 99.5% of introns and 
the minor spliceosome, which 
removes the remaining 0.5%.
What are spliceosomes made of? 
Spliceosomes contain both proteins 
and RNAs. Yeasts have ~100 
spliceosomal proteins, whereas over 
300 different proteins associate with 
human spliceosomes (Figure 1A). 
Many of these proteins have specifi c 
RNA recognition activities, while 
others are NTPases that function 
to drive the overall process forward 
and ensure its fi delity. Numerous 
other proteins bind stably to small 
nuclear RNAs (snRNAs) to form small 
nuclear RNPs (snRNPs, pronounced 
‘snurps’). Major spliceosomes are 
assembled from U1, U2, U4, U6, 
and U5 snRNPs (which are named 
according to the U snRNA(s) they 
contain); minor spliceosomes are 
assembled from U11, U12, U4atac, 
U5, and U6atac snRNPs (Figure 1B).
How did the various spliceosomal 
parts get their names? The U 
snRNAs were originally discovered 
as abundant small uridine-rich RNA 
molecules present in mammalian 
nuclei, and they were initially 
numbered in order of their apparent 
abundance. U1, U2, U4, U5, U6, 
U11, and U12 were later found to be 
spliceosome components. U7 snRNA 
is required for histone mRNA 3-end 
processing; the other abundant 
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Figure 1. Spliceosome components and assembly.
(A) Protein and snRNA composition of yeast spliceosomes (akin to the ‘major’ metazoan spliceo-
some). Also shown are the conserved sequences of major (A) and minor (B) introns (solid line) with 
exons (boxes), and intronic consensus sequences (most highly conserved nucleotides in red). NTC, 
nineteen complex; NTR, nineteen complex related. SS, splice site; BP, branch point. ‘Sm’ indicates 
the seven Sm proteins, i.e. B, D1, D2, D3, E, F, and G; ‘Lsm’ indicates the seven Lsm proteins, i.e. 
Lsm2, Lsm3, Lsm4, Lsm5, Lsm6, Lsm7, and Lsm8. (B) Components  of the minor spliceosome. 
snRNPs contain  the indicated  snRNAs plus stably bound proteins, many of which are shared 
with the major spliceosome. NTC and NTR association with the minor spliceosome has only been 
inferred to date. (C) Simplifi ed spliceosome assembly scheme showing the two chemical steps of 
splicing. See text for details.U snRNAs (U3, U8, U9 and U10) are 
all involved in ribosome biogenesis.  
U4atac and U6atac are much less 
abundant than other spliceosomal 
snRNAs, so were only discovered 
and named when it was realized that 
there must be other snRNAs that 
recognize the minor intron class. The 
fi rst and last two DNA nucleotides of 
minor introns are most often AT and 
AC, respectively (Figure 1B), hence 
the names U4atac and U6atac.
Many spliceosomal proteins 
have PRP names, e.g. Prp2, Prp5, Prp8, etc. (Figure 1A). In yeast, 
mutations in these genes lead to 
‘pre-mRNA processing’ defects. 
Confusingly, orthologous genes 
can have different PRP names in 
Saccharomyces cerevisiae and 
Schizosaccharomyces pombe 
because the original mutational 
screens were performed around 
the same time and a unifi ed naming 
system has yet to be devised. Other 
core spliceosomal proteins include 
CWC (complexed with CDC5), CWF 
(complexed with CDC fi ve), SPF (sensitivity to Pichia farinosa killer 
toxin), SYF (synthetic lethal with 
cdcforty). The nineteen complex 
(NTC) is a large protein-only 
subcomplex named after its most 
abundant component, Prp19, while 
another small protein-only complex 
known as NTR (nineteen complex 
related) contains factors involved in 
spliceosome disassembly. 
Some major spliceosomal 
proteins were first discovered in 
vertebrates. The seven Sm proteins, 
which form a ring encircling a 
specific binding site in almost all 
spliceosomal snRNAs, were named 
after the patient (Smith) with whose 
autoimmune antibodies they react. 
A similar set of proteins (Lsm, 
for ‘like Sm’) were later found to 
encircle U6 and U6atac snRNAs, 
the only two spliceosomal snRNAs 
lacking a consensus Sm-binding 
site. Two additional large classes 
of metazoan splicing factors are 
the hnRNP proteins, so-called 
because they are found associated 
with heterogeneous nuclear RNA 
(hnRNA), and the SR proteins, 
named for a carboxy-terminal 
domain rich in arginine-serine (RS) 
dipeptides. 
How does the spliceosome do its 
job? Spliceosomes must excise 
non-coding introns from precursor 
transcripts and stitch the flanking 
exons back together to create 
mature spliced mRNAs. To do so, 
the splicing machinery assembles 
in a stepwise manner on the ends of 
introns, with U1 snRNP recognizing 
the beginning of an intron (5 splice 
site, the donor site) and U2 snRNP 
recognizing a feature (the branch 
site) at the other end in the vicinity 
of the 3 splice site (acceptor 
site). After numerous structural 
rearrangements that involve both 
the addition of new components 
and the ejection of many others, 
splicing occurs in two chemical 
steps: firstly, cleavage at the 5 
splice site coupled to formation of 
a lariat structure in which the first 
nucleotide of the intron is linked 
via a 2–5 phosphodiester bond 
to the branch site adenosine; and 
secondly, ligation of the two exons, 
coupled to cleavage at the 3 splice 
site (Figure 1C). The spliceosome 
then disassembles from the excised 
intron, which is subsequently 
debranched and degraded. 
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Since ancient times, people have cut 
and joined together plants of different 
varieties or species so they would 
grow as a single plant — a process 
known as grafting (Figures 1 and 2). 
References to grafting appear in the 
Bible, ancient Greek and ancient 
Chinese texts, indicating that grafting 
was practised in Europe, the Middle 
East and Asia by at least the 5th 
century BCE. It is unknown where or 
how grafting was fi rst discovered, 
but it is likely that natural grafting, the 
process by which two plants touch 
and fuse limbs or roots in the absence 
of human interference (Figure 3), 
infl uenced people’s thinking. Such 
natural grafts are generally uncommon, 
but are seen in certain species, 
including English ivy. Parasitic plants, 
such as mistletoe, that grow and feed 
on often unrelated species may have 
also contributed to the development 
of grafting as a technique, as people 
would have observed mistletoe 
growing on trees such as apples or 
poplars.
Today, plant grafting is widely used 
in orchards, greenhouses, vineyards 
and gardens. One common application 
is grafting the shoot of one plant, 
termed the scion, to the root of a 
different plant, termed the rootstock, 
to increase or decrease the size of 
the plant. Alternatively, grafting can 
improve stress resistance or allow 
plants to grow in new environments. 
Plant grafting has also been important 
for the discovery of proteins, RNAs 
and hormones that act over long 
distances. This Primer summarises 
the mechanisms of graft formation, 
discusses why some plants graft 
whereas other do not, and describes 
how grafting is important for 
agriculture and for scientifi c research. 
The mechanism of graft formation 
Although grafting has been practised 
for over 2500 years, ancient texts often 
gave confusing and contradictory 
information about what plants could be 
successfully grafted together, known 
as compatible grafts, and which plants 
could not, known as incompatible 
PrimerHow do spliceosomes affect gene expression? Because the vast 
majority of protein-coding genes in 
humans contain introns (typically 
9 or 10, but some have more than 
100!), splicing is an essential step in 
gene expression. High-throughput 
sequencing has now revealed that 
~95% of human genes are also 
subject to alternative splicing, 
which allows for the synthesis of 
many different mRNAs from a single 
DNA gene. By encoding alternative 
protein isoforms or harboring 
different regulatory sequences 
in their untranslated regions, 
alternatively spliced mRNAs greatly 
enhance biological complexity. 
The act of splicing itself also has 
important consequences for gene 
expression beyond intron removal. 
By stably depositing on exons 
proteins that accompany mRNPs 
to the cytoplasm (e.g. the exon 
junction complex, EJC), splicing can 
affect the subcellular localization, 
translation effi ciency and decay 
kinetics of the mRNA. In particular, 
mRNA decay driven by EJC location 
relative to the stop codon is a 
crucial mediator of cellular protein 
abundance. 
Are spliceosomes associated 
with any diseases? Many human 
diseases are caused by either mis-
splicing of a single gene or mis-
regulation of the entire spliceosome. 
Around 35% of human genetic 
disorders are caused by a mutation 
that alters the splicing of a single 
gene. Such mutations can add/
remove a single splice site (e.g., 
- or -thalassemia) or shift the 
balance of alternative splicing by 
affecting the inclusion/exclusion of a 
cassette exon (e.g., frontotemporal 
dementia driven by tau mis-splicing). 
Some mis-splicing events generate 
an mRNA isoform that is subject 
to rapid degradation. Single point 
mutations that affect splicing can 
thereby result in large changes 
to both protein structure and 
protein abundance. Other diseases 
are caused by mutations in the 
splicesomal proteins themselves, 
thereby affecting splicing of many 
transcripts. For example, mutations 
in several core spliceosomal 
proteins (e.g., Prp8, Prp3, Prp31, 
and Brr2) have been shown to 
cause autosomal dominant retinitis 
pigmentosa. Mutations in splicing factor 3B subunit 1 (SF3B1) and 
U2 auxiliary factor 35 (U2AF35) 
are frequently associated with 
chronic lymphocytic leukaemia and 
myelodysplasia. Other cancers are 
associated with mis-regulation of 
splicing factor levels. Therefore, the 
spliceosome has recently emerged 
as a new target for the development 
of novel anti-cancer therapies.
What remains to be explored? 
Because of its highly dynamic and 
complex nature, an atomic level 
structure of the spliceosome remains 
an elusive goal. Nonetheless, much 
progress has recently been made by 
crystallizing subsets of spliceosomal 
components, including U1 and U4 
snRNPs and the central core protein 
Prp8. Other major questions regard 
the exact molecular mechanisms 
by which spliceosomes achieve 
high splicing accuracy, while 
simultaneously allowing for fl exibility 
in splice site choice to permit 
alternative splicing. To answer 
these questions, new tools such 
as single-molecule microscopy, 
bioinformatics, and high-throughput 
methods for determining protein–
protein, protein–RNA and RNA–RNA 
interaction dynamics are increasingly 
being developed and applied. 
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